GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gubra AS (CHIX:GUBRAc) » Definitions » Capex-to-Operating-Income

Gubra AS (CHIX:GUBRAC) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Gubra AS Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Gubra AS's Capital Expenditure for the six months ended in Dec. 2023 was kr-7.37 Mil. Its Operating Income for the six months ended in Dec. 2023 was kr-24.86 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Gubra AS Capex-to-Operating-Income Historical Data

The historical data trend for Gubra AS's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gubra AS Capex-to-Operating-Income Chart

Gubra AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
- 0.45 0.31 - -

Gubra AS Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial - - 0.90 - -

Competitive Comparison of Gubra AS's Capex-to-Operating-Income

For the Biotechnology subindustry, Gubra AS's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gubra AS's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gubra AS's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Gubra AS's Capex-to-Operating-Income falls into.



Gubra AS Capex-to-Operating-Income Calculation

Gubra AS's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-11.196) / -47.667
=N/A

Gubra AS's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-7.365) / -24.857
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gubra AS  (CHIX:GUBRAc) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Gubra AS Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Gubra AS's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Gubra AS (CHIX:GUBRAC) Business Description

Industry
Traded in Other Exchanges
Address
Hørsholm Kongevej 11B, Hørsholm, DNK, 2970
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases.

Gubra AS (CHIX:GUBRAC) Headlines

No Headlines